Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

SummaryQuotesChartsNewsCalendarCompany 
News SummaryMost relevantAll newsSector newsTweets 

St. Jude Medical, Inc. : St Jude To Stop Selling Another Version Of Defibrillator Wires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 03:48pm CEST

St. Jude Medical Inc. (STJ) will stop selling another version of its defibrillator wires in an effort to head off potential problems like those the medical-device maker is currently battling with its Riata and Riata ST wires.

The Riata defibrillator wires, called leads, are no longer on the market but are still implanted in thousands of patients in the U.S. In a medical journal last month, prominent cardiologist Robert G. Hauser wrote that the cables are responsible for at least 20 deaths.

Wednesday, the company said it will cease selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart. Roughly 171,000 QuickSite and QuickFlex leads have been sold worldwide.

The decision comes as St. Jude has confirmed 39 cases of the metal wires wearing through their silicone covering, leading to an incidence rate of 2.3 in every 10,000 leads. Still, it stressed that its decision to stop selling the wires is a proactive one.

"It is important to note, however, that the overall safety and reliability of QuickSite and QuickFlex leads continues to be comparable to currently available CRT leads from other manufacturers," the company wrote.

The wire leads connect life-saving medical devices, which are placed under the skin in the shoulder area, to the heart and delivers a jolt that restores proper rhythm. Because of the constant pounding motion of the heart, the thin leads can be damaged.

Shares closed Tuesday at $43.80 and were inactive in premarket trading. The stock is up roughly 36% from lows hit late last year when the Food and Drug Administration termed the Riata defibrillator issues as a Class I recall, which applies to grave dangers like chance of death.

 
   -By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected] 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ST. JUDE MEDICAL, INC.
04/20 ST JUDE MEDICAL : Federal Contracts Awarded by Federal Agencies in Iowa (April 2..
04/20 ST JUDE MEDICAL : Patent Issued for Staged Deployment Devices and Methods for Tr..
04/20 ST JUDE MEDICAL : Patent Issued for Commissure Attachment Feature for Prosthetic..
04/19 ABBOTT LABORATORIES : profit rises 33 percent after St. Jude Medical deal
04/19 ST JUDE MEDICAL : $25,235 Federal Contract Awarded to St. Jude Medical
04/19 ST JUDE MEDICAL : $120,060 Federal Contract Awarded to St. Jude Medical
04/18 ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
04/17 MEDCOMTECH : Special Notice - SPINAL IMPLANTS
04/15 ABBOTT LABORATORIES : FDA Demands St. Jude Take Action on Medical Device Securit..
04/13 ST JUDE MEDICAL : Patent Issued for Method and Apparatus for the Cancellation of..
More news
Sector news : Medical Devices & Implants
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Medical Devices & Implants
News from SeekingAlpha
04/18 Abbott-Alere Deal To Go Ahead
02/17 GLAZER CAPITAL : Merger Arbitrage With Convertibles - A Lower Risk Alternative
02/15 Panel To Stand Sentinel Over Embolic Filter
02/01 Dividend Champions For February 2017
01/25 U.S. Medtech Approvals Dip, But Could Pick Up In 2017
Advertisement
Chart ST. JUDE MEDICAL, INC.
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Managers
NameTitle
Michael T. Rousseau President, Chief Executive Officer & Director
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
Mark W. Murphy Chief Information Officer & Vice President-IT
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ST. JUDE MEDICAL, INC.0.79%0
STRYKER CORPORATION13.67%50 584
SMITH & NEPHEW PLC4.26%14 206
WRIGHT MEDICAL GROUP N..31.98%3 143
GLAUKOS CORP36.65%1 597
OSSTEM IMPLANT CO LTD--.--%689
More Results